Development and in vitro Profiling of Dual FXR/LTA4H Modulators

Area of Science:

• Pharmacology
• Hepatology
• Drug Discovery

Background:

• Non-alcoholic steatohepatitis (NASH) is a complex liver disease characterized by steatosis, inflammation, and fibrosis.
• Targeting multiple pathways simultaneously (polypharmacology) is a promising strategy for multifactorial diseases like NASH.
• Activation of farnesoid X receptor (FXR) and inhibition of leukotriene A4 hydrolase (LTA4H) are identified as key mechanisms to counteract NASH.

Purpose of the Study:

• To develop and evaluate dual FXR/LTA4H modulators as pharmacological tools for NASH treatment.
• To assess the potential of polypharmacology in addressing the multifaceted pathology of NASH.
• To create a well-balanced dual-acting molecule for probing therapeutic synergies.

Main Methods:

• Design and synthesis of dual polypharmacology agents targeting FXR and LTA4H.
• In vitro evaluation of compound activity, potency, and selectivity against intended and off-target molecules.
• Assessment of dual FXR/LTA4H modulators as tools for studying NASH pathogenesis and treatment.

Main Results:

• Development of optimized dual FXR/LTA4H modulators with sub-micromolar potency.
• Demonstration of well-balanced dual activity on both FXR and LTA4H targets.
• High selectivity of the developed compounds over related nuclear receptors and enzymes.

Conclusions:

• Dual modulation of FXR and LTA4H represents a viable polypharmacology strategy for NASH.
• The developed dual FXR/LTA4H modulators are suitable pharmacological tools for further investigation.
• This approach holds potential for developing novel therapeutics for non-alcoholic steatohepatitis.